Shingrix to replace Zostavax with lower age cut-off in NIP shake-up

A two-dose schedule with an interval of 2-6 months is recommended for most patients.

The recombinant herpes zoster vaccine, Shingrix, will soon replace the live-attenuated vaccine, Zostavax, on the National Immunisation Program following advice from the PBAC and ATAGI, the government has confirmed.

Patients aged 65 and over, immunocompromised adults at high risk of zoster infection and Aboriginal and Torres Strait Islander patients aged 50 and over will be eligible for free vaccination from 1 November.